Cash from Operations (Annual) Chart

View Cash from Operations (Annual) for IBRX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Annual) Chart
Start Trial

Historical Cash from Operations (Annual) Data

View and export this data back to 2013. Start Trial.
Date Value
December 31, 2025 -304.94M
December 31, 2024 -391.24M
December 31, 2023 -366.76M
December 31, 2022 -337.51M
December 31, 2021 -274.42M
December 31, 2020 -70.45M
December 31, 2019 -61.36M
Date Value
December 31, 2018 -63.38M
December 31, 2017 -48.78M
December 31, 2016 -38.59M
December 31, 2015 -25.30M
December 31, 2014 -5.418M
December 31, 2013 -0.668M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Annual) Range, Past 5 Years

View Cash from Operations (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Annual) Benchmarks

View Cash from Operations (Annual) Benchmarks
Start Trial
Moderna, Inc. -1.873B
Sarepta Therapeutics, Inc. -222.54M
Arrowhead Pharmaceuticals, Inc. 179.55M
Oncolytics Biotech, Inc. -20.11M
Sangamo Therapeutics, Inc. -97.21M